World's Best Scientists 2026 revealed!
Richard D. Gelber

Richard D. Gelber

D-Index & Metrics

Medicine

D-Index
161
Citations
137489
World Ranking
732
National Ranking
415

Richard D. Gelber publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard D. Gelber sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 665 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard D. Gelber D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard D. Gelber sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 161 D-Index — 96th percentile

96% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1993 - Fellow of the American Statistical Association (ASA)

Overview

Richard D. Gelber is affiliated with Harvard University in the United States. Their research spans multiple areas primarily within medicine and biochemistry, genetics, and molecular biology, with a focus on oncology and cancer-related studies.

Their work encompasses the following main fields of study:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

More specific areas of investigation within these fields include:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Genetics
  • Radiology, Nuclear Medicine and Imaging

Richard D. Gelber's research topics cover a range of themes related to cancer and its treatment, such as:

  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Advanced Breast Cancer Therapies
  • Cancer Treatment and Pharmacology
  • Cancer Risks and Factors
  • Estrogen and related hormone effects
  • Monoclonal and Polyclonal Antibodies Research

They have co-authored extensively with the following researchers:

  • Martine Piccart (44 collaborations)
  • Marco Colleoni (33 collaborations)
  • Giuseppe Viale (29 collaborations)
  • Evandro de Azambuja (24 collaborations)
  • Aron Goldhirsch (21 collaborations)

The primary publication venues for Richard D. Gelber's work include:

  • Journal of Clinical Oncology (19 publications)
  • Cancer Research (14 publications)
  • Breast Cancer Research and Treatment (7 publications)
  • Annals of Oncology (5 publications)
  • The Breast (5 publications)

Recent notable papers authored or co-authored by Richard D. Gelber include:

  • "Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer," 2021, New England Journal of Medicine
  • "Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer," 2022, Annals of Oncology
  • "Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up," 2021, Journal of Clinical Oncology
  • "Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials," 2021, The Lancet Oncology
  • "Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer," 2023, New England Journal of Medicine

Richard D. Gelber was awarded the status of Fellow of the American Statistical Association (ASA) in 1993.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

    Edward M. Connor;Rhoda S. Sperling;Richard Gelber;Pavel Kiselev

  • Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

    A. Goldhirsch;W.C. Wood;A.S. Coates;R.D. Gelber

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

    C Focan;SM Steinberg;M Blichert-Toft;JF Forbes

  • Reduction of maternal-infant transmission of human immunodeficiency virus 1 with zidovudine treatment

    Edward M. Connor;Rhoda S. Sperling;Richard Gelber;Pavel Kiselev

  • A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

    Beat Thürlimann;Aparna Keshaviah;Alan S Coates

  • Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    A. S. Coates;E. P. Winer;A. Goldhirsch;R. D. Gelber

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

    Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume

  • Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

    Aron Goldhirsch;J. N. Ingle;R. D. Gelber;A. S. Coates

  • Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood

    Steven E. Lipshultz;Steven D. Colan;Richard D. Gelber;Antonio R. Perez-Atayde

  • American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

    Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff

  • Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

    José Baselga;José Baselga;Ian Bradbury;Holger Eidtmann;Serena Di Cosimo;Serena Di Cosimo

  • Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

    A. Goldhirsch;J. H. Glick;R. D. Gelber;A. S. Coates

  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

    Gunter von Minckwitz;Marion Procter;Evandro de Azambuja;Dimitrios Zardavas

  • Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

    Viviana Galimberti;Bernard F. Cole;Bernard F. Cole;Stefano Zurrida;Giuseppe Viale;Giuseppe Viale

  • Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007

    A. Goldhirsch;W. C. Wood;R. D. Gelber;A. S. Coates

  • Analysis of survival by tumor response.

    James R. Anderson;Kevin C. Cain;Richard D. Gelber

  • Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

    Lewis B. Silverman;Richard D. Gelber;Virginia Kimball Dalton;Barbara L. Asselin

Frequent Co-Authors

Aron Goldhirsch
Aron Goldhirsch European Institute of Oncology
Alan S. Coates
Alan S. Coates University of Sydney
Karen N. Price
Karen N. Price Frontier Science Foundation
Giuseppe Viale
Giuseppe Viale University of Milan
Marco Colleoni
Marco Colleoni European Institute of Oncology
Meredith M. Regan
Meredith M. Regan Harvard University
Beat Thürlimann
Beat Thürlimann Kantonsspital St. Gallen
Stephen E. Sallan
Stephen E. Sallan Harvard University
Evandro de Azambuja
Evandro de Azambuja Université Libre de Bruxelles
John F. Forbes
John F. Forbes University of Limerick

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in healthcare but not ready to commit to a traditional MD program, there are flexible online alternatives that can launch or advance a medical career. Online nursing programs offer students foundational knowledge and hands-on skills required for various clinical roles. These programs are ideal for both newcomers and those looking to shift into the medical field.

For practicing nurses aiming to deepen expertise and pursue advanced practice or research roles, online nursing PhD programs make doctoral education accessible and affordable. Meanwhile, the cheapest online RN to BSN programs provide a convenient path for registered nurses to earn a bachelor’s degree and open doors to higher-level positions.

If you hold a non-nursing bachelor’s degree but want to join the nursing profession, entry level MSN programs online offer accelerated routes to a master’s degree in nursing. These diverse pathways make it easier than ever to start or advance a healthcare career—without the need for traditional, on-campus education.

Best Scientists Citing Richard D. Gelber

Trending Scientists

Recently Published Articles